Li et al. indicated that the combination of sulforaphane with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin synergistically inhibited cell growth in vitro and in pancreatic cancer xenograft model in vivo, by decreasing the function of Hsp90 and increasing the activity of caspase-3 [41]. This evidence concerns the gene CASP3 and pancreatic neoplasm.